Convalescent plasma for outpatients with early COVID-19

Pere Millat-Martinez; Arvind Gharbharan; Andrea Alemany; Casper Rokx; Corine Geurtsvankessel; Grigorios Papageourgiou; Nan van Geloven; Carlijn Jordans; Geert Groeneveld; Francis Swaneveld; Ellen van der Schoot; Marc Corbacho-Monné; Dan Ouchi; Francini Piccolo Ferreira; Pierre Malchair; Sebastian Videla; Vanesa García García; Anna Ruiz-Comellas; Anna Ramírez-Morros; Joana Rodríguez Codina; Rosa Amado Simon; Joan-Ramon Grifols; Julian Blanco; Ignacio Blanco; Jordi Ara; Quique Bassat; Bonaventura Clotet; Bàrbara Baro; Andrea Troxel; Jaap Jan Zwaginga; Oriol Mitjà; Bart Rijnders; for the ConV-ert; CoV-Early and COMPILEhome study groups

doi:10.1101/2021.11.30.21266810

Abstract

Background Convalescent plasma (CP) for hospitalized patients with COVID-19 has not demonstrated clear benefits. However, data on outpatients with early symptoms are scarce. We aimed to assess whether treatment with CP administered during the first 7 days of symptoms reduced the disease progression or risk of hospitalization of outpatients.

Methods Two double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of their predefined sample size had been recruited. A Bayesian adaptive individual patient data meta-analysis was implemented. Analyses were done with Bayesian proportional odds and logistic models, where odds ratios (OR)<1.0 indicate a favorable outcome for CP. Fourteen study sites across the Netherlands and Catalonia in Spain participated in the trial. The two studies included outpatients aged ≥50 years and diagnosed with COVID-19 and symptomatic for ≤7days. The intervention consisted of one unit (200-300mL) of CP with a predefined minimum level of antibodies. The two primary endpoints were (a) a 5-point disease severity scale (fully recovered by day 7 or not, hospital or ICU admission and death) and (b) a composite of hospitalization or death.

Results Of 797 patients included, 390 received CP and 392 placebo. At baseline, they had a median age of 58 years, 1 comorbidity, symptoms for 5 days and 93% tested negative for SARS-CoV-2 S-protein IgG antibodies. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The OR of CP for an improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311). The OR for hospitalization or death was 0.919 (CI 0.592-1.416). The effect of CP on hospital admission or death was largest in patients with ≤5 days of symptoms (OR 0.658, 95% CI 0.394-1.085). CP did not decrease the time to full symptom resolution (p=0.62).

Conclusion Treatment with CP of outpatients in the first 7 days of symptoms did not improve the outcome of COVID-19. The possible beneficial effect in patients with ≤5 days of symptoms requires further study.

Registration NCT04621123 and NCT04589949 on https://www.clinicaltrials.gov

Funding source ZONMW, the Netherlands, grant number 10430062010001.

SUPPORT-E, grant number 101015756

YoMeCorono, www.tomecorono.com

The Fight AIDS and Infectious Diseases Foundation with funding from the pharmaceutical company Grifols S.A

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

The COnV-ert study (NCT04621123) and the CoV-Early study (NCT04589949)

Funding Statement

This study was funded by: ZONMW, the Netherlands, grant number 10430062010001. SUPPORT‐E, grant number 101015756 YoMeCorono, www.tomecorono.com The Fight AIDS and Infectious Diseases Foundation with funding from the pharmaceutical company Grifols S.A

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The COnV-ert study received approval from the Institutional Review Board of the Hospital Germans Trias I Pujol (reference PI 20-313) and the CoV-Early study received approval from the Institutional Review Board of the Erasmus Medical Centre Rotterdam (reference MEC-2020-0682).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes